<DOC>
	<DOC>NCT01145417</DOC>
	<brief_summary>This study examines the safety of pregabalin over a 6 month period in patients with neuropathic pain associated with HIV infection as an extension of another trial that tests the efficacy of pregabalin.</brief_summary>
	<brief_title>Pregabalin Trial In HIV Neuropathic Pain</brief_title>
	<detailed_description>The parent double blind study was stopped at interim analysis due to lack of efficacy and therefore this open label extension study was also terminated simultaneously on April 2, 2012; the termination was unrelated to any safety findings that could impact patient health.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Subjects who participated in the preceding A0081244 doubleblind trial and completed at least through Visit 9 of that trial. Subjects with painful distal sensory polyneuropathy (DSP) interested in treatment based on investigator's clinical judgment. Subjects who had acceptable tolerability of study drug in A0081244. Clinically significant or unstable conditions that, in the opinion of the investigator, would compromise participation in the study. This includes, for example, medical conditions such as, but not limited to: hepatic, renal, respiratory, hematological, immunological, cardiovascular diseases, arrhythmia, inflammatory or rheumatologic disease, active infections, symptomatic peripheral vascular disease, psychiatric illness, and untreated endocrine disorders. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. Active Acquired Immune Deficiency Syndrome (AIDS) defining Opportunistic Infection (OI) that requires hospitalization.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>peripheral neuropathic pain</keyword>
	<keyword>pregabalin</keyword>
	<keyword>safety</keyword>
</DOC>